Our Impact, Your Health


Precision medicine is a continuously evolving field which tailors a patient’s needs to individualised therapies. It bridges the gap in therapeutic selection, matching new highly targeted medications to a specific subsets of patients for which they are predicted to be most effective.

The Cardiometabolic Disease Epidemic

The increasing epidemic of obesity has impacted all demographics of the global population. This threat has exacerbated the incidence of debilitating and life-threatening diseases. There is currently a lack of available diagnostic and monitoring methods for early stages of these diseases. This is especially prevalent in organs such as the liver, kidney, and heart. In particular there has been an explosion of drug development activity for treating liver damage associated with obesity and metabolic diseases such as Nonalcoholic Steatohepatitis (NASH). Molecular Stethoscope has developed a cf-mRNA assay for stratification of NASH by disease severity. Current diagnostic methods, including biopsy, are inadequate. There is an urgent clinical need for an accurate, non-invasive approach. Molecular Stethoscope is partnering with pharmaceutical companies to assist in therapeutic development and plans to commercially offer a diagnostic test to physicians and patients in the near future.

Inflammation – Mapping the Site and Composition of Treatable Disease

Cell-free mRNA can serve as a blood-based diagnostic for the measurement of organ specific inflammation. Historically, measurement of the type and extent of inflammation within an organ has only been possible via direct biopsy. These procedures have associated risks, are painful and in some cases impossible. Over the past decade, there has been a proliferation of highly specific and expensive disease modifying drugs which are largely prescribed on an empirical basis. Molecular Stethoscope’s cf-mRNA technology enables early detection, quantitation and characterization of inflammation, resulting in more precise treatment decisions. This encompasses very broad opportunities from transplant medicine, autoimmunity to chronic inflammation. Molecular Stethoscope is currently conducting studies in graft versus host disease (GVHD).

Drug Development Enablement

Clinically useful biomarkers facilitate the delivery of new drugs to the right patients faster than currently possible. Circulating cf-mRNA from a single tube of blood provides information useful in toxicology, pharmacodynamics, patient stratification, therapeutic response, and monitoring of end-organ damage, aiding pharmaceutical companies in drug development.